1SXP — SCHOTT Pharma AG & Co KgaA Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapFalling Star

Annual income statement for SCHOTT Pharma AG & Co KgaA, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.

	2020 September 30th	2021 September 30th	2022 September 30th	2023 September 30th	2024 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	—	—	—	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	584	649	821	899	957
Cost of Revenue
Gross Profit	196	226	296	316	323
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	486	521	657	706	765
Operating Profit	98.2	128	164	192	193
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	95.3	123	158	186	184
Provision for Income Taxes
Net Income After Taxes	77.6	101	126	152	150
Minority Interest
Net Income Before Extraordinary Items
Net Income	77.5	101	125	152	150
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	77.5	101	125	152	150
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.511	0.667	0.886	0.971	0.991
Dividends per Share